Bellicum Pharmaceuticals Receives a Buy from Cantor Fitzgerald

By Austin Angelo

Cantor Fitzgerald analyst Elemer Piros reiterated a Buy rating on Bellicum Pharmaceuticals (NASDAQ: BLCM) today and set a price target of $32. The company’s shares closed yesterday at $14.09.

Piros commented:

“Clinical Progress with BP-004. On the call, management outlined its progress in the BP-004 European registration trial, which will be complemented by a matched unrelated donor (MUD) comparator trial. Bellicum expects to complete enrollment for both BP-004 and MUD trials by the end of the year, with an MAA filing expected in mid-2018. Management highlighted that, since the last data release, additional cases of GvHD have been reported, and the profile of BPX-501 and rimiducid remains encouraging.”

According to TipRanks.com, Piros is a 1-star analyst with an average return of -1.9% and a 48.8% success rate. Piros covers the Healthcare sector, focusing on stocks such as Dimension Therapeutics Inc, Conatus Pharmaceuticals, and Zynerba Pharmaceuticals.

Bellicum Pharmaceuticals has an analyst consensus of Moderate Buy.

Based on Bellicum Pharmaceuticals’ latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $114K and GAAP net loss of $17.72 million. In comparison, last year the company earned revenue of $34K and had a GAAP net loss of $16.85 million.

Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Bellicum Pharmaceutivals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors, as well as orphan inherited blood disorders. The company develops chemical induction of dimerization technology platform to engineer and control components of the immune system. Bellicum Pharmaceutivals was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX.